Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.12.2014 | short review

Contribution of the vascular bone marrow niche to leukemia progression

verfasst von: Jasmin Wellbrock, Walter Fiedler, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Leukemia arises from leukemic stem cells, which reside within the bone marrow occupying two different stem cells niches: the endosteal and the vascular niche. The maintenance of leukemic stem cells requires complex regulation mediated by many intrinsic and extrinsic signals provided by their niche cells. The interaction of leukemic and endothelial cells can occur either via direct contact through cell adhesion molecules such as selectins or integrins or signals can be transmitted by chemokines or cytokines of which stromal cell-derived factor 1 represents the most studied. Experimental studies provide evidence that targeting molecules involved in the interaction of leukemic and endothelial cells might represent a promising therapeutic target. Indeed, first clinical trials considering this concept are currently under investigation.
Vorheriger Artikel ASCO 2014: news, hopes, hypes?
Nächster Artikel Angiogenesis inhibition, hypoxia, and targeting the bone marrow microenvironment in multiple myeloma: new strategies and targets
Literatur
1.
2.
Doan PL, Chute JP. The vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia. 2012;26:54–62.PubMedCrossRef
3.
Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870–5.PubMed
4.
Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000;96:2240–5.PubMed
5.
6.
Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol. 2011;29:591–9.PubMedCrossRef
7.
Mohle R, Bautz F, Rafii S, Moore MA, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. Blood. 1998;91:4523–30.PubMed
8.
Rombouts EJ, Pavic B, Lowenberg B, Ploemacher RE. Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia. Blood. 2004;104:550–7.PubMedCrossRef
9.
Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 2007;21:1249–57.PubMedCrossRef
10.
Liesveld JL, Bechelli J, Rosell K, Lu C, Bridger G, Phillips G, 2nd, et al. Effects of AMD3100 on transmigration and survival of acute myelogenous leukemia cells. Leuk Res. 2007;31:1553–63.PubMedCentralPubMedCrossRef
11.
Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009;113:6215–24.PubMedCentralPubMedCrossRef
12.
Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C, et al. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica. 2012;97:608–15.PubMedCentralPubMedCrossRef
13.
Herrmann H, Cerny-Reiterer S, Sadovnik I, Winter V, Blatt K, Rabitsch W, et al. Identification of Novel Surface Markers and Targets in Neoplastic Stem Cells in AML and CML: a Flow-Gene-Flow Screen Approach. Blood (ASH Annual Meeting Abstracts). 2010;116:3382.CrossRef
14.
Smith-Berdan S, Nguyen A, Hassanein D, Zimmer M, Ugarte F, Ciriza J, et al. Robo4 cooperates with CXCR4 to specify hematopoietic stem cell localization to bone marrow niches. Cell Stem Cell. 2011;8:72–83.PubMedCentralPubMedCrossRef
15.
Smith-Berdan S, Schepers K, Ly A, Passegue E, Forsberg EC. Dynamic expression of the Robo ligand Slit2 in bone marrow cell populations. Cell Cycle. 2012;11:675–82.PubMedCrossRef
16.
ter Huurne M, Figdor CG, Torensma R. Hematopoietic stem cells are coordinated by the molecular cues of the endosteal niche. Stem Cells Dev. 2010;19:1131–41.PubMedCrossRef
17.
Mazo IB, Gutierrez-Ramos JC, Frenette PS, Hynes RO, Wagner DD, von Andrian UH. Hematopoietic progenitor cell rolling in bone marrow microvessels: parallel contributions by endothelial selectins and vascular cell adhesion molecule 1. J Exp Med. 1998;188:465–74.PubMedCentralPubMedCrossRef
18.
Winkler IG, Barbier V, Nowlan B, Jacobsen RN, Forristal CE, Patton JT, et al. Vascular niche E-selectin regulates hematopoietic stem cell dormancy, self renewal and chemoresistance. Nat Med. 2012;18:1651–7.PubMedCrossRef
19.
Pezeshkian B, Donnelly C, Tamburo K, Geddes T, Madlambayan GJ. Leukemia mediated endothelial cell activation modulates leukemia cell susceptibility to chemotherapy through a positive feedback loop mechanism. PLoS One. 2013;8:e60823.PubMedCentralPubMedCrossRef
20.
Krause DS, Lazarides K, Lewis JB, von Andrian UH, Van Etten RA. Selectins and their ligands are required for homing and engraftment of BCR-ABL1+ leukemic stem cells in the bone marrow niche. Blood. 2014;123:1361–71.PubMedCrossRef
21.
Wicklein D, Schmidt A, Labitzky V, Ullrich S, Valent P, Schumacher U. E- and p-selectins are essential for repopulation of chronic myelogenous and chronic eosinophilic leukemias in a scid mouse xenograft model. PLoS One. 2013;8:e70139.PubMedCentralPubMedCrossRef
22.
Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, Shido K, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med. 2004;10:64–71.PubMedCrossRef
23.
Williams DA, Rios M, Stephens C, Patel VP. Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature. 1991;352:438–41.PubMedCrossRef
24.
Rettig MP, Ansstas G, DiPersio JF. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia. 2012;26:34–53.PubMedCentralPubMedCrossRef
25.
Matsunaga T, Takemoto N, Sato T, Takimoto R, Tanaka I, Fujimi A, et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med. 2003;9:1158–65.PubMedCrossRef
26.
Magyarosy E, Sebestyen A, Timar J. Expression of metastasis associated proteins, CD44v6 and NM23-H1, in pediatric acute lymphoblastic leukemia. Anticancer Res. 2001;21:819–23.PubMed
27.
Zarcone D, De Rossi G, Tenca C, Marroni P, Mauro FR, Cerruti GM, et al. Functional and clinical relevance of CD44 variant isoform expression on B-cell chronic lymphocytic leukemia cells. Haematologica. 1998;83:1088–98.PubMed
28.
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12:1167–74.PubMedCrossRef
29.
Charrad RS, Li Y, Delpech B, Balitrand N, Clay D, Jasmin C, et al. Ligation of the CD44 adhesion molecule reverses blockage of differentiation in human acute myeloid leukemia. Nat Med. 1999;5:669–76.PubMedCrossRef
30.
Wellbrock J, Fiedler W. Clinical experience with antiangiogenic therapy in leukemia. Curr Cancer Drug Targets. 2011;11:1053–68.PubMedCrossRef
Metadaten
Titel
Contribution of the vascular bone marrow niche to leukemia progression
verfasst von
Jasmin Wellbrock
Walter Fiedler, MD
Publikationsdatum
01.12.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0149-5

Weitere Artikel der Ausgabe 4/2014

Gene signature profiling of gynaecological malignancies

  • short review

Post ASCO update 2014: head and neck cancer

  • review

Towards automation of flow cytometric analysis for quality-assured follow-up assessment to guide curative therapy for acute lymphoblastic leukaemia in children

  • special report

Is there a role for angiogenesis inhibition in prostate cancer?

  • review

Lung cancer: ASCO 2014 update

  • short review

Angiogenesis inhibition in renal cell cancer

  • short review